s*6
2 楼
大家为什么看好 DNDN ？技术上不错，但其 business 怎样？能支持大幅度上扬么？
p*a
3 楼
You should have bought around $4. Current level has too much risk.
【在 c*****l 的大作中提到】
: 试试看
【在 c*****l 的大作中提到】
: 试试看
c*l
4 楼
回调到4 继续买。呵呵
【在 p****a 的大作中提到】
: You should have bought around $4. Current level has too much risk.
【在 p****a 的大作中提到】
: You should have bought around $4. Current level has too much risk.
c*l
5 楼
涨疯了 LOL
c*l
6 楼
Dendreon has been one of the worst-performing biotech stocks over the last
two years amid reimbursement issues for its Provenge prostate cancer drug
and other problems, but Bernstein said Friday that interviews with the drug
’s “busiest prescribers” showed they are not only increasing their use
but recruiting others to use the product as well. With that, Bernstein
forecasted “slow but steady revenue growth” for Dendreon and said it sees
signs the “progressive disaster” at the company could be coming to an end.
The firm raised its price target by 43% to $10/share and upped the stock to
an outperform rating. Shares of heavily shorted Dendreon–short interest
was 30% at year-end–surged 13% to $5.78 in premarket trade.
two years amid reimbursement issues for its Provenge prostate cancer drug
and other problems, but Bernstein said Friday that interviews with the drug
’s “busiest prescribers” showed they are not only increasing their use
but recruiting others to use the product as well. With that, Bernstein
forecasted “slow but steady revenue growth” for Dendreon and said it sees
signs the “progressive disaster” at the company could be coming to an end.
The firm raised its price target by 43% to $10/share and upped the stock to
an outperform rating. Shares of heavily shorted Dendreon–short interest
was 30% at year-end–surged 13% to $5.78 in premarket trade.
c*l
7 楼
DNDN 今天全部出掉 发个消息
c*l
8 楼
不要吵 你屁大灾天 可以吧 跟你不熟 无视
相关阅读